AR056763A1 - Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen. - Google Patents
Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen.Info
- Publication number
- AR056763A1 AR056763A1 ARP060104841A ARP060104841A AR056763A1 AR 056763 A1 AR056763 A1 AR 056763A1 AR P060104841 A ARP060104841 A AR P060104841A AR P060104841 A ARP060104841 A AR P060104841A AR 056763 A1 AR056763 A1 AR 056763A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- aliphatic
- con
- so2n
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Reivindicacion 1: Un compuesto de la formula (1) o una de sus sales farmacéuticamente aceptables, en donde: Ht es tiazol, o pirazol, en donde cada anillo está opcional e independientemente sustituido con R2 y R2'; Q es -O-, -NR'-, -S- o -C(R')2-; Rx es H, alifático C1-6, NO2, CN, halo, NH2, N(alifático C1-4), N(alifático C1-4)2, O(alifático C1-4), OH o -N(C=O)(alifático C1-4); en donde dicho alifático está opcionalmente sustituido con 1-3 fluoro; Ry es T2-R10 o L-Z-R10; R1 es T3-(anillo D); anillo D es un anillo arilo o heteroarilo monocíclico de 5-7 miembros, en donde dicho heteroarilo tiene 1-4 heteroátomos del anillo seleccionados de O, N y S; anillo D puede estar opcionalmente fusionado con el anillo D'; anillo D' es un anillo de 5- 8 miembros, aromático, parcialmente saturado o totalmente insaturado que contiene 0-4 heteroátomos del anillo seleccionados de N, O o S; cada C del anillo sustituible del anillo D y anillo D' está sustituido, de modo independiente, con oxo, T4-R5 o V-Z-R5; cada N del anillo sustituible del anillo D y anillo D' está sustituido, de modo independiente, con -R4; cada T, T3 y T4 es, de modo independiente, una cadena alquilideno C1-4 o está ausente; Z es una cadena alquilideno C1-4 o está ausente; L es -O-, -S-, -SO-, -SO2-, -N(R6)SO2-, -SO2N(R6)-, -N(R6)-, -CO-, -CO2-, -N(R6)CO-, -N(R6)C(O)O-, -N(R6)CON(R6)-, -N(R6)SO2N(R6)-, -N(R6)N(R6)-, -C(O)N(R6)-, -OC(O)N(R6)-, -C(R6)2O-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2SO2-, -C(R6)2SO2N(R6)-, -C(R6)2N(R6)- , -C(R6)2N(R6)C(O)-, -C(R6)2N(R6)C(O)O-, -C(R6)=NN(R6)-, -C(R6)=N-O-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)SO2N(R6)- o -C(R6)2N(R6)CON(R6)-; T2 está, de modo independiente, ausente o es una cadena alquilideno C1-10 en donde hasta seis unidades C de la cadena alquilideno están opcionalmente reemplazadas por -O-, -C(=O)-, -S(O)-, -S(O)2-, -S- o -N(R4)-; T2 está opcionalmente sustituido con 0-6 grupos JT; R2 y R2' son, de modo independiente, -R, -T-W-R6 o R8 o R2 y R2' se toman juntos con sus átomos intervinientes para formar un anillo fusionado, de 5-8 miembros, insaturado o parcialmente insaturado con 0-3 heteroátomos del anillo seleccionados de N, O o S, en donde cada C del anillo sustituible de dicho anillo fusionado formado por R2 y R2' está sustituido, de modo independiente, con halo, oxo, -CN, -NO2, -R7 o -V-R6 y cada N del anillo sustituible de dicho anillo formado por R2 y R2' está sustituido, de modo independiente, con R4; R5 es -R, -halo, -OR, -C(=O)R, -CO2R, -COCOR, COCH2COR, -NO2, -CN, -S(O)R, -S(O)2R, -SR, -N(R4)2, -CON(R7)2, -SO2N(R7)2, -OC(=O)R, -N(R7)COR, -N(R7)CO2(alifático C1-6), -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N(R7)CON(R7)2, -N(R7)SO2N(R7)2, -N(R4)SO2R o -OC(=O)N(R7)2; cada R es H, un grupo alifático C1-10, un anillo arilo C6-10, un anillo heteroarilo con 5-10 átomos del anillo o un anillo heterociclilo con 4-10 átomos del anillo, donde el anillo heteroarilo o heterociclilo tiene 1-4 heteroátomos del anillo seleccionados de N, O o S, el grupo alifático y cada R está opcionalmente sustituido con 0-6 R9; cada R4 es -R7,-COR7, -CO2(alifático C1-6 opcionalmente sustituido), -CON(R7)2 o -SO2R7; V es -O-, -S-, -SO-, -SO2-, -N(R6)SO2-, -SO2N(R6)-, -N(R6)-, -CO-, -CO2-, -N(R6)CO-, - N(R6)C(O)O-, -N(R6)CON(R6)-, -N(R6)SO2N(R6)-, -N(R6)N(R6)-, -C(O)N(R6)-, -OC(O)N(R6)-, -C(R6)2O-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2SO2-, -C(R6)2SO2N(R6)-, -C(R6)2N(R6)-, -C(R6)2N(R6)C(O)-, -C(R6)2N(R6)C(O)O-, -C(R6)=NN(R6)-, -C(R6)=N-O-, - C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)SO2N(R6)- o -C(R6)2N(R6)CON(R6)-; W es -C(R6)2O-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2SO2-, -C(R6)2SO2N(R6)-, -C(R6)2N(R6)-, -CO-, -CO2-, -C(R6)2OC(O)-, -C(R6)2OC(O)N(R6)-, -C(R6)2N(R6)CO-, -C(R6)2N(R6)C(O)O-, -C(R6)=NN(R6)- , -C(R6)=N-O-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)SO2N(R6)- -C(R6)2N(R6)CON(R6)- o -CON(R6)-; cada R6 es, de modo independiente, H o alifático C1-6 opcionalmente sustituido con 0-3 J6; o dos grupos R6 en el mismo átomo de N se toman juntos con el átomo de N para formar un anillo heterociclilo o heteroarilo de 4-8 miembros; en donde dicho anillo heterociclilo o heteroarilo está opcionalmente sustituido con 0-4 J6; cada R7 es, de modo independiente, H; alifático C1-6; un heteroarilo de 5 miembros que contiene 0-4 heteroátomos seleccionados de O, N o S; o fenilo, cada R7 está opcionalmente sustituido con 0-3 J7; o dos R7 en el mismo N se toman juntos con el N para formar un anillo heterociclilo o heteroarilo opcionalmente sustituido de 4-8 miembros; en donde dicho anillo heterociclilo o heteroarilo está opcionalmente sustituido con 0-4 J7; cada R8 es halogeno, -CN o -NO2; cada R9 es -R', -halo, -OR', -C(=O)R', -CO2R', -COCOR', COCH2COR', -NO2, -CN, -S(O)R', -S(O)2R', -SR', -N(R')2, - CON(R')2, -SO2N(R')2, -OC(=O)R', -N(R')COR', -N(R')CO2(alifático C1-6), -N(R')N(R')2, --N(R')CON(R')2, -N(R')SO2N(R')2, -N(R')SO2R', -OC(=O)N(R')2; =N-OR' o =O; cada R10 es un anillo heterocíclico de 4 miembros que contiene un heteroátomo seleccionado de O, NR11 y S; cada R10 está opcionalmente sustituido con 0-6 ocurrencias de J; cada J y JT es, de modo independiente, -R, -halo, -OR, -C(=O)R, -CO2R, -COCOR, COCH2COR, -NO2, -CN, -S(O)R, -S(O)2R, -SR, -N(R4)2, -CON(R7)2, -SO2N(R7)2, - OC(=O)R, -N(R7)COR, -N(R7)CO2(alifático C1-6), -N(R4)N(R4)2, =NN(R4)2, =N-OR, =NR, =O, -N(R7)CON(R7)2, -N(R7)SO2N(R7)2, -N(R4)SO2R, -OC(=O)N(R7)2 o -OP(=O)(ORö)2; o cada J6 y J7 es, de modo independiente, NH2, NH(alifático C1-4), N(alifático C1-4)2, halogeno, alifático C1-4, OH, O(alifático C1-4), NO2, CN, CO2H, CO2(alifático C1-4), O(haloalifático C1-4) o haloalifático C1-4; 2 grupos J o JT, en el mismo átomo o en átomos diferentes, junto con los átomos a los que cada grupo J o JT están unidos, forman un anillo de 3-8 miembros saturado, parcialmente saturado o insaturado con 0-2 heteroátomos seleccionados de O, N o S; en donde 1-4 átomos de H en el anillo formado por los 2 grupos J o JT está opcionalmente reemplazado con halo, alquilo C1-3 o -O(alquilo C1-3); en donde dicho alquilo C1-3 está opcionalmente sustituido con 1-3 F; o dos átomos de H en el mismo átomo en el anillo formado por los 2 grupos J o JT están opcionalmente reemplazados con oxo; cada R11 es -R7, -CR7, - CO2(alifático C1-6 opcionalmente sustituido), -CON(R7)2 o -SO2R7; cada R' es, de modo independiente, H o un grupo alifático C1-6 opcionalmente sustituido con 0-4 ocurrencias de NH2, NH(alifático C1-4), N(alifático C1-4)2, halogeno, alifático C1-4, OH, O(alifático C1-4), NO2, CN, CO2H, CO2(alifático C1-4), CONH2, CONH(alifático C1-4), CON(alifático C1-4)2, O(haloalifático C1-4) o haloalifático C1-4; o dos R', junto con los átomos a los que están unidos, forman =O, un carbociclilo o heterociclilo opcionalmente sustituido de 3-6 miembros; cada Rö es, de modo independiente, H o alquilo C1-2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73295105P | 2005-11-03 | 2005-11-03 | |
US73355705P | 2005-11-04 | 2005-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056763A1 true AR056763A1 (es) | 2007-10-24 |
Family
ID=38023840
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104842A AR057874A1 (es) | 2005-11-03 | 2006-11-03 | Aminopirimidinas utiles como inhibidores de quinasa |
ARP060104841A AR056763A1 (es) | 2005-11-03 | 2006-11-03 | Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen. |
ARP060104843A AR056764A1 (es) | 2005-11-03 | 2006-11-03 | Aminopirimidinas utiles como inhibidores de quinasa |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104842A AR057874A1 (es) | 2005-11-03 | 2006-11-03 | Aminopirimidinas utiles como inhibidores de quinasa |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104843A AR056764A1 (es) | 2005-11-03 | 2006-11-03 | Aminopirimidinas utiles como inhibidores de quinasa |
Country Status (18)
Country | Link |
---|---|
US (7) | US7767672B2 (es) |
EP (3) | EP1954277B1 (es) |
JP (5) | JP5249771B2 (es) |
KR (3) | KR20080067694A (es) |
CN (3) | CN101316843B (es) |
AR (3) | AR057874A1 (es) |
AU (3) | AU2006311831C1 (es) |
BR (3) | BRPI0619704A2 (es) |
CA (3) | CA2627857A1 (es) |
ES (2) | ES2435081T3 (es) |
IL (3) | IL191043A0 (es) |
MX (3) | MX2008005814A (es) |
NO (3) | NO20082517L (es) |
NZ (4) | NZ594383A (es) |
RU (5) | RU2427578C2 (es) |
SG (2) | SG166827A1 (es) |
TW (3) | TW200736249A (es) |
WO (3) | WO2007056221A2 (es) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
WO2004072029A2 (en) | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
RU2405780C2 (ru) * | 2005-02-16 | 2010-12-10 | Астразенека Аб | Химические соединения |
BRPI0610184A2 (pt) * | 2005-05-16 | 2012-09-25 | Astrazeneca Ab | composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica |
US7795279B2 (en) * | 2005-10-18 | 2010-09-14 | Janssen Pharmaceutica Nv | Method of inhibiting FLT3 kinase |
DK1945631T3 (da) * | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer |
CA2627857A1 (en) | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
AU2006315334B2 (en) * | 2005-11-16 | 2011-05-19 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
EP2016074B1 (en) | 2006-04-20 | 2016-01-13 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
CA2668429A1 (en) | 2006-11-02 | 2008-05-15 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
CA2673353A1 (en) | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
ES2435997T3 (es) | 2007-03-09 | 2013-12-26 | Vertex Pharmaceuticals, Inc. | Aminopirimidinas útiles como inhibidores de las proteínas cinasas |
EP2134709A1 (en) | 2007-03-09 | 2009-12-23 | Vertex Pharmaceuticals, Inc. | Aminopyridines useful as inhibitors of protein kinases |
NZ579485A (en) * | 2007-03-09 | 2012-02-24 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
CA2683785A1 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
JP2010524911A (ja) * | 2007-04-18 | 2010-07-22 | アストラゼネカ アクチボラグ | 5−アミノピラゾール−3−イル−3H−イミダゾ[4,5−b]ピリジン誘導体と癌の治療のためのその使用 |
EP2155730A2 (en) * | 2007-05-02 | 2010-02-24 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
CN101801959A (zh) * | 2007-05-02 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶类化合物 |
JP5389785B2 (ja) | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なチアゾールおよびピラゾール |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
US20100204231A1 (en) * | 2007-05-04 | 2010-08-12 | Astrazeneca Ab | Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancer |
CN101687852A (zh) * | 2007-05-24 | 2010-03-31 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的噻唑类和吡唑类化合物 |
EP2166849A4 (en) * | 2007-06-11 | 2010-09-15 | Miikana Therapeutics Inc | SUBSTITUTED PYRAZOL COMPOUNDS |
CA2694499A1 (en) * | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
CA2695753A1 (en) * | 2007-08-15 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as protein kinases inhibitors |
EP3078662A1 (en) | 2007-09-21 | 2016-10-12 | Array Biopharma, Inc. | Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
WO2009086012A1 (en) * | 2007-12-20 | 2009-07-09 | Curis, Inc. | Aurora inhibitors containing a zinc binding moiety |
WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
US8324199B2 (en) * | 2008-03-13 | 2012-12-04 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
BRPI0908708A2 (pt) * | 2008-03-17 | 2019-09-24 | Scripps Research Inst | métodos para produzir células tronco pluripotentes induzidas a partir de células não pluripotentes de mamífero, para triar quanto a agentes que induzam a reprogramação ou desdiferenciação de células de mamífero dentro das células tronco pluripotentes, para triar quanto a células de mamífero com características de células tronco pluripotente, para induzir a expressão de oct4 em uma célula e para induzir células não pluripotentes em células pluripotentes, mistura, célula de mamífero, métodos para produzir células tronco pluripotentes induzidas a partir de células não pluripotentes de mamífero, para triar quanto a agentes que induzam a reprogramação ou desiferenciação de células de mamífero dentro das células tronco pluripotentes, para triar quanto a células de mamífero com características de célula tronco pluripotente, para induzir a expressão de oct4 em uma célula e para induzir células não pluripotentes em células pluripotentes, mistura, célula de mamífero, composição, e, kit |
RU2010154502A (ru) * | 2008-06-11 | 2012-07-20 | Астразенека Аб (Se) | Трициклические 2,4-диамино-l,3,5-триазиновые производные, пригодные для лечения злокачественного новообразования и миелопролиферативных нарушений |
NZ621143A (en) * | 2008-09-05 | 2016-08-26 | Celgene Avilomics Res Inc | Algorithm for designing irreversible inhibitors |
KR20110071098A (ko) * | 2008-09-30 | 2011-06-28 | 아스트라제네카 아베 | 복소환 jak 키나제 억제제 |
BRPI0923579A2 (pt) | 2008-12-22 | 2020-01-14 | Millennium Pharm Inc | combinação de inibidores de aurora quinase e anticorpos anti-cd20 |
JP2012529527A (ja) * | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | ウレイドフェニル置換トリアジン誘導体類及びそれらの治療応用 |
CN102713618B (zh) * | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
CA2785738A1 (en) | 2009-12-30 | 2011-07-07 | Avila Therapeutics, Inc. | Ligand-directed covalent modification of protein |
WO2012000103A1 (en) | 2010-07-02 | 2012-01-05 | University Health Network | Methods of targeting pten mutant diseases and compositions therefor |
US9120749B2 (en) * | 2010-07-30 | 2015-09-01 | Oncotherapy Science, Inc. | Quinoline derivatives and MELK inhibitors containing the same |
US9382229B2 (en) | 2011-02-15 | 2016-07-05 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
CN105254616B (zh) | 2011-07-27 | 2017-10-17 | 阿斯利康(瑞典)有限公司 | 取代的n‑(2‑甲氧基‑5‑硝基苯基)嘧啶‑2‑胺化合物及其盐 |
JP2014524456A (ja) | 2011-08-25 | 2014-09-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | セリン/スレオニンpak1阻害剤 |
EP2754659A4 (en) * | 2011-09-05 | 2015-08-26 | Zhejiang Hisun Pharm Co Ltd | 4-SUBSTITUTED- (3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO) -PYRIMIDINES DERIVATIVES HAVING PROTEIN KINASE INHIBITION ACTIVITY AND USE THEREOF |
CN104185420B (zh) | 2011-11-30 | 2017-06-09 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
CN104011050A (zh) | 2011-12-22 | 2014-08-27 | 霍夫曼-拉罗奇有限公司 | 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物 |
JP6134376B2 (ja) | 2012-03-16 | 2017-05-24 | アクシキン ファーマシューティカルズ インコーポレーテッド | 3,5−ジアミノピラゾールキナーゼ阻害剤 |
EP2841428B1 (en) | 2012-04-24 | 2018-08-22 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
US9539259B2 (en) | 2012-05-23 | 2017-01-10 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
MX367055B (es) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa. |
WO2014071378A1 (en) * | 2012-11-05 | 2014-05-08 | Nant Holdings Ip, Llc | Substituted indol-5-ol derivatives and their therapeutical applications |
DK3527563T3 (da) | 2013-03-12 | 2021-12-06 | Vertex Pharma | Dna-pk-inhibitorer |
JP2016514703A (ja) | 2013-03-15 | 2016-05-23 | ナントバイオサイエンス、インコーポレイテッド | 置換インドール−5−オール誘導体及びそれらの治療適用 |
US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
US10335494B2 (en) | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
MX2017008526A (es) | 2014-12-23 | 2017-10-25 | Axikin Pharmaceuticals Inc | Inhibidores de 3,5-diaminopirazol quinasa. |
EP3302465A1 (en) | 2015-06-05 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
CA3038657A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
PL3555074T3 (pl) * | 2016-12-14 | 2022-11-07 | Intervet International B.V. | Aminopirazole jako selektywne inhibitory kinaz janusowych |
BR112019013593A2 (pt) | 2016-12-28 | 2020-01-07 | Minoryx Therapeutics S.L. | Compostos de isoquinolina, métodos para sua preparação, e usos terapêuticos dos mesmos em afecções associadas à alteração da atividade de beta galactosidase |
CN106841420A (zh) * | 2016-12-30 | 2017-06-13 | 广州中大南沙科技创新产业园有限公司 | 一种LC‑MS/MS测定大鼠血浆中Ly‑7u浓度的方法 |
WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
CN110132795A (zh) * | 2019-05-20 | 2019-08-16 | 华核(天津)新技术开发有限公司 | 放射性去污效率测试方法 |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
AU2021230288A1 (en) * | 2020-03-06 | 2022-09-01 | National Health Research Institutes | Pyrimidine compounds and their pharmaceutical uses |
WO2021222637A1 (en) | 2020-04-30 | 2021-11-04 | United States Government As Represented By The Department Of Veterans Affairs | Krüppel-like factor 15 (klf15) small molecule agonists in kidney disease |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133081A (en) * | 1964-05-12 | J-aminoindazole derivatives | ||
US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
BE754242A (fr) * | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
DE2458965C3 (de) * | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
MA18829A1 (fr) | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
DOP1981004033A (es) | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
SE8102194L (sv) | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
SE8102193L (sv) | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
JPS58124773A (ja) | 1982-01-20 | 1983-07-25 | Mitsui Toatsu Chem Inc | 5−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤 |
EP0136976A3 (de) | 1983-08-23 | 1985-05-15 | Ciba-Geigy Ag | Verwendung von Phenylpyrimidinen als Pflanzenregulatoren |
DE3725638A1 (de) | 1987-08-03 | 1989-02-16 | Bayer Ag | Neue aryloxy (bzw. thio)aminopyrimidine |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5597920A (en) | 1992-04-30 | 1997-01-28 | Neurogen Corporation | Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes |
JPH0665237A (ja) | 1992-05-07 | 1994-03-08 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
WO1995009851A1 (en) | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
KR970706813A (ko) | 1994-11-10 | 1997-12-01 | 찰스 홈시 | 단백질 키나아제의 억제물질로서 유용한 제약용 피라졸 조성물(pharmaceutical pyrazole compositions useful as inhibitors of protein kinases) |
IL117659A (en) | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
US5935966A (en) | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
AU726058B2 (en) | 1995-09-01 | 2000-10-26 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
JPH10130150A (ja) | 1996-09-05 | 1998-05-19 | Dainippon Pharmaceut Co Ltd | 酢酸アミド誘導体からなる医薬 |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
US6251911B1 (en) | 1996-10-02 | 2001-06-26 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
BR9712530A (pt) | 1996-10-11 | 1999-10-19 | Warner Lambert Co | Inibidores de ésteres de asparato de enzima de conversão de interleucina-1beta |
AU741203B2 (en) | 1997-10-10 | 2001-11-22 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
JP2000026421A (ja) | 1998-01-29 | 2000-01-25 | Kumiai Chem Ind Co Ltd | ジアリ―ルスルフィド誘導体及び有害生物防除剤 |
WO1999041253A1 (en) * | 1998-02-17 | 1999-08-19 | Tularik Inc. | Anti-viral pyrimidine derivatives |
US6153591A (en) | 1998-03-16 | 2000-11-28 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
EP1082120A1 (en) | 1998-06-02 | 2001-03-14 | OSI Pharmaceuticals, Inc. | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
ATE274510T1 (de) | 1998-06-19 | 2004-09-15 | Chiron Corp | Glycogen synthase kinase 3 inhibitoren |
WO2000011003A1 (en) | 1998-08-21 | 2000-03-02 | Du Pont Pharmaceuticals Company | ISOXAZOLO[4,5-d]PYRIMIDINES AS CRF ANTAGONISTS |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
KR100860295B1 (ko) | 1998-10-08 | 2008-09-25 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
DK1171465T3 (da) | 1999-03-29 | 2004-12-13 | Uutech Ltd | Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
BR0104424A (pt) * | 2000-02-05 | 2002-01-08 | Vertex Pharma | Composições de pirazol úteis como inibidores de erk |
AU3704101A (en) | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
ES2240446T3 (es) | 2000-04-03 | 2005-10-16 | Vertex Pharma | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. |
PL360439A1 (en) * | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
HU229997B1 (en) | 2000-07-21 | 2015-04-28 | Dendreon Corp San Diego | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
AP2001002266A0 (en) | 2000-08-31 | 2001-09-30 | Pfizer Prod Inc | Pyrazole derivatives. |
EP1317450B1 (en) * | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
HUP0302991A3 (en) | 2000-09-15 | 2009-10-28 | Vertex Pharma | Isoxazoles and their use as inhibitors of erk and pharmaceutical compositions containing the compounds |
US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6641579B1 (en) | 2000-09-29 | 2003-11-04 | Spectrasonics Imaging, Inc. | Apparatus and method for ablating cardiac tissue |
US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
DE10061863A1 (de) | 2000-12-12 | 2002-06-13 | Basf Ag | Verfahren zur Herstellung von Triethylendiamin (TEDA) |
NZ526471A (en) * | 2000-12-21 | 2005-08-26 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
US6759983B2 (en) * | 2001-03-28 | 2004-07-06 | Strategic Analysis, Inc. | Method and device for precise geolocation of low-power, broadband, amplitude-modulated signals |
MXPA03008888A (es) * | 2001-03-29 | 2005-03-07 | Vertex Pharma | Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas. |
MXPA03009378A (es) * | 2001-04-13 | 2004-01-29 | Vertex Pharma | Inhibidores de cinasas c-jun n-terminales (jnk) y otras proteinas cinasas. |
EP1383771A1 (en) * | 2001-04-20 | 2004-01-28 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
EP1404669A2 (en) * | 2001-05-16 | 2004-04-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
EP1399440B1 (en) | 2001-06-15 | 2009-06-03 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
WO2003004492A1 (en) * | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
US6698980B2 (en) * | 2001-07-30 | 2004-03-02 | Stewart Mining Products Inc. | Rock stabilizing apparatus and method |
WO2003026664A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
US6569499B2 (en) * | 2001-10-02 | 2003-05-27 | Xerox Corporation | Apparatus and method for coating photoreceptor substrates |
ATE466581T1 (de) * | 2001-12-07 | 2010-05-15 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
US7863282B2 (en) * | 2003-03-14 | 2011-01-04 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US7091343B2 (en) * | 2002-03-15 | 2006-08-15 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
EP1485380B1 (en) | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines as inhibitors of protein kinases |
ES2289279T3 (es) * | 2002-03-15 | 2008-02-01 | Vertex Pharmaceuticals Incorporated | Composiciones utiles como inhibidores de proteinquinasas. |
WO2003078426A1 (en) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azolylaminoazine as inhibitors of protein kinases |
US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
EP1506189A1 (en) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
JP4570955B2 (ja) * | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
PT1532145E (pt) * | 2002-08-02 | 2007-01-31 | Vertex Pharma | Composiçoes de pirazole úteis como inibidores de gsk-3 |
US7262200B2 (en) | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
JP2004224944A (ja) * | 2003-01-24 | 2004-08-12 | Kuraray Plast Co Ltd | 高周波接着性に優れた熱可塑性樹脂組成物 |
DE602004022187D1 (de) | 2003-10-17 | 2009-09-03 | Astrazeneca Ab | 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs |
MY141220A (en) * | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
KR20080038369A (ko) | 2005-07-28 | 2008-05-06 | 버텍스 파마슈티칼스 인코포레이티드 | 카스파제 억제제 프로드럭 |
CA2619517A1 (en) | 2005-08-18 | 2007-02-22 | Michael Mortimore | Pyrazine kinase inhibitors |
WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
WO2007041358A2 (en) * | 2005-09-30 | 2007-04-12 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
CA2627857A1 (en) * | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
AU2006315334B2 (en) | 2005-11-16 | 2011-05-19 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
CA2668429A1 (en) * | 2006-11-02 | 2008-05-15 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
CA2673353A1 (en) * | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
ES2523863T3 (es) * | 2006-12-29 | 2014-12-02 | Janssen R&D Ireland | Pirimidinas 5,6-sustituidas inhibidoras del VIH |
NZ579485A (en) | 2007-03-09 | 2012-02-24 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
EP2134709A1 (en) * | 2007-03-09 | 2009-12-23 | Vertex Pharmaceuticals, Inc. | Aminopyridines useful as inhibitors of protein kinases |
ES2435997T3 (es) * | 2007-03-09 | 2013-12-26 | Vertex Pharmaceuticals, Inc. | Aminopirimidinas útiles como inhibidores de las proteínas cinasas |
CA2682195A1 (en) * | 2007-03-20 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
WO2008131103A2 (en) * | 2007-04-17 | 2008-10-30 | Vertex Pharmaceuticals Incorporated | Drug discovery methods for aurora kinase inhibitors |
EP2155730A2 (en) * | 2007-05-02 | 2010-02-24 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
CN101801959A (zh) | 2007-05-02 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶类化合物 |
JP5389785B2 (ja) | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なチアゾールおよびピラゾール |
CN101687852A (zh) * | 2007-05-24 | 2010-03-31 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的噻唑类和吡唑类化合物 |
WO2010108162A1 (en) | 2009-03-20 | 2010-09-23 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
-
2006
- 2006-11-03 CA CA002627857A patent/CA2627857A1/en not_active Abandoned
- 2006-11-03 NZ NZ594383A patent/NZ594383A/xx not_active IP Right Cessation
- 2006-11-03 TW TW095140891A patent/TW200736249A/zh unknown
- 2006-11-03 RU RU2008122048/04A patent/RU2427578C2/ru not_active IP Right Cessation
- 2006-11-03 WO PCT/US2006/043096 patent/WO2007056221A2/en active Application Filing
- 2006-11-03 US US11/592,114 patent/US7767672B2/en active Active
- 2006-11-03 EP EP06836938.8A patent/EP1954277B1/en not_active Not-in-force
- 2006-11-03 AR ARP060104842A patent/AR057874A1/es not_active Application Discontinuation
- 2006-11-03 JP JP2008539071A patent/JP5249771B2/ja not_active Expired - Fee Related
- 2006-11-03 CN CN2006800444148A patent/CN101316843B/zh not_active Expired - Fee Related
- 2006-11-03 BR BRPI0619704-3A patent/BRPI0619704A2/pt not_active IP Right Cessation
- 2006-11-03 KR KR1020087013424A patent/KR20080067694A/ko not_active Application Discontinuation
- 2006-11-03 CA CA002627808A patent/CA2627808A1/en not_active Abandoned
- 2006-11-03 AR ARP060104841A patent/AR056763A1/es not_active Application Discontinuation
- 2006-11-03 US US11/592,113 patent/US7820685B2/en active Active
- 2006-11-03 AU AU2006311831A patent/AU2006311831C1/en not_active Ceased
- 2006-11-03 CA CA002627830A patent/CA2627830A1/en not_active Abandoned
- 2006-11-03 JP JP2008539091A patent/JP5328361B2/ja not_active Expired - Fee Related
- 2006-11-03 AU AU2006311797A patent/AU2006311797A1/en not_active Abandoned
- 2006-11-03 TW TW095140878A patent/TW200734327A/zh unknown
- 2006-11-03 NZ NZ606259A patent/NZ606259A/en not_active IP Right Cessation
- 2006-11-03 SG SG201008116-4A patent/SG166827A1/en unknown
- 2006-11-03 MX MX2008005814A patent/MX2008005814A/es active IP Right Grant
- 2006-11-03 WO PCT/US2006/042994 patent/WO2007056164A2/en active Application Filing
- 2006-11-03 US US11/592,119 patent/US7528142B2/en active Active
- 2006-11-03 AR ARP060104843A patent/AR056764A1/es not_active Application Discontinuation
- 2006-11-03 NZ NZ594385A patent/NZ594385A/xx not_active IP Right Cessation
- 2006-11-03 EP EP06827465.3A patent/EP1951715B1/en not_active Not-in-force
- 2006-11-03 CN CN2012105636245A patent/CN103145702A/zh active Pending
- 2006-11-03 JP JP2008539070A patent/JP5249770B2/ja not_active Expired - Fee Related
- 2006-11-03 TW TW095140900A patent/TW200736250A/zh unknown
- 2006-11-03 RU RU2008122070/04A patent/RU2008122070A/ru not_active Application Discontinuation
- 2006-11-03 ES ES06827465T patent/ES2435081T3/es active Active
- 2006-11-03 CN CN2006800445831A patent/CN101316597B/zh not_active Expired - Fee Related
- 2006-11-03 WO PCT/US2006/042993 patent/WO2007056163A2/en active Application Filing
- 2006-11-03 BR BRPI0619708-6A patent/BRPI0619708A2/pt not_active IP Right Cessation
- 2006-11-03 EP EP06836890.1A patent/EP1948193B1/en not_active Not-in-force
- 2006-11-03 NZ NZ606263A patent/NZ606263A/en not_active IP Right Cessation
- 2006-11-03 ES ES06836890.1T patent/ES2533241T3/es active Active
- 2006-11-03 BR BRPI0619706-0A patent/BRPI0619706A2/pt not_active IP Right Cessation
- 2006-11-03 MX MX2008005818A patent/MX2008005818A/es active IP Right Grant
- 2006-11-03 AU AU2006311830A patent/AU2006311830B2/en not_active Ceased
- 2006-11-03 MX MX2008005717A patent/MX2008005717A/es active IP Right Grant
- 2006-11-03 KR KR1020087013281A patent/KR20080066069A/ko not_active Application Discontinuation
- 2006-11-03 KR KR1020087013419A patent/KR20080067693A/ko not_active Application Discontinuation
- 2006-11-03 RU RU2008122046/04A patent/RU2423361C2/ru not_active IP Right Cessation
- 2006-11-03 SG SG201008117-2A patent/SG166828A1/en unknown
-
2008
- 2008-04-27 IL IL191043A patent/IL191043A0/en unknown
- 2008-04-27 IL IL191044A patent/IL191044A0/en unknown
- 2008-04-29 IL IL191140A patent/IL191140A0/en unknown
- 2008-05-30 NO NO20082517A patent/NO20082517L/no not_active Application Discontinuation
- 2008-05-30 NO NO20082514A patent/NO20082514L/no not_active Application Discontinuation
- 2008-05-30 NO NO20082508A patent/NO20082508L/no not_active Application Discontinuation
-
2009
- 2009-03-25 US US12/410,553 patent/US8129399B2/en active Active
-
2010
- 2010-06-08 US US12/796,297 patent/US8637511B2/en active Active
- 2010-09-30 US US12/894,465 patent/US8557833B2/en active Active
-
2011
- 2011-04-04 RU RU2011112948/15A patent/RU2011112948A/ru not_active Application Discontinuation
- 2011-05-05 RU RU2011118227/15A patent/RU2011118227A/ru not_active Application Discontinuation
- 2011-12-02 US US13/309,970 patent/US20120142660A1/en not_active Abandoned
-
2012
- 2012-12-12 JP JP2012271604A patent/JP2013049731A/ja active Pending
- 2012-12-19 JP JP2012276504A patent/JP2013075904A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056763A1 (es) | Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen. | |
AR042397A1 (es) | Compuestos de pirazol utiles como inhibidores de proteinquinasa | |
AR067762A1 (es) | Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
AR044909A1 (es) | Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia | |
AR071823A1 (es) | Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos. | |
AR084312A1 (es) | Compuestos triciclicos inhibidores de la pi3k y composiciones farmaceuticas | |
AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
AR091498A1 (es) | DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
AR069326A1 (es) | Derivados bis-(sulfonilamino), proceso de preparacion, composiciones farmaceuticas que los contienen y su uso en terapia. | |
UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
AR048537A1 (es) | Derivados de nucleosidos para tratar infecciones por virus de hepatitis c. | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
AR069772A1 (es) | Derivados heterociclicos, una composicion farmaceutica y un juego que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de una infeccion parasitaria. | |
AR086468A1 (es) | Compuestos heterociclos biciclicos y sus usos en terapia | |
AR086403A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
AR061891A1 (es) | Derivados de benzofuro-y benzotienopirimidina, composiciones farmaceuticas que los contienen y usos en trastornos alergicos, dermatologicos y autoinmunes. | |
AR048607A1 (es) | Derivados (poli)aminoalquilaminoacetamida de la epipodofilotoxina, proceso de preparacion de los mismos y sus aplicaciones terapeuticas como agentes anticancerosos | |
PE20231312A1 (es) | Derivados triciclicos de carboxamida como inhibidores de la prmt5 | |
CY1124245T1 (el) | Τρικυκλικα συγχωνευμενα παραγωγα πυριδινης-2-ενα και η χρηση τους ως αναστολεις brd4 | |
AR115007A1 (es) | Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |